UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers

Singh, Amandeep; Singh, Vikash; Wallis, Nadav; Abis, Giancarlo; Oberman, Froma; Wood, Tyler; Dhamdhere, Mayura; ... Sharma, Arun K; + view all (2024) Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers. European Journal of Medicinal Chemistry , 263 , Article 115940. 10.1016/j.ejmech.2023.115940. Green open access

[thumbnail of Supplementary Material_Revised.pdf]
Preview
Text
Supplementary Material_Revised.pdf - Accepted Version

Download (5MB) | Preview
[thumbnail of Ramos_AVJ_manuscript_EJMC_Revised final.pdf]
Preview
Text
Ramos_AVJ_manuscript_EJMC_Revised final.pdf

Download (1MB) | Preview

Abstract

IGF2BP1 is a protein that controls the stability, localization, and translation of various mRNA targets. Poor clinical outcomes in numerous cancer types have been associated with its overexpression. As it has been demonstrated to impede tumor growth and metastasis in animal models, inhibiting IGF2BP1 function is a promising strategy for combating cancer. A lead chemical, 7773, which specifically decreased IGF2BP1 RNA binding and cellular activities, was previously identified in a high-throughput screen for effective IGF2BP1 inhibitors. Additional optimization of 7773 described in this manuscript led to the discovery of six compounds that performed equally well or better than 7773. In cell lines with high levels of endogenous IGF2BP1, one of 7773 derivatives, AVJ16, was found to be most efficient at preventing cell migration. Further, AVJ16 was found to be IGF2BP1-specific because it had no effect on cell lines that expressed little or no IGF2BP1 protein. The direct binding of AVJ16 to IGF2BP1 was validated by binding tests, with a 12-fold increase in binding efficiency over the lead compound. AVJ16 was shown to bind to a hydrophobic region at the protein's KH34 di-domain interface between the KH3 and KH4 domains. Overall, the findings imply that AVJ16 is a potent and specific inhibitor of IGF2BP1 activity.

Type: Article
Title: Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers
Location: France
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ejmech.2023.115940
Publisher version: http://dx.doi.org/10.1016/j.ejmech.2023.115940
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: IGF2BP1; High-throughput screen; Structure-activity relationship; Wound healing; 15N-HSQC
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Div of Biosciences > Structural and Molecular Biology
URI: https://discovery.ucl.ac.uk/id/eprint/10186563
Downloads since deposit
Loading...
59Downloads
Download activity - last month
Loading...
Download activity - last 12 months
Loading...
Downloads by country - last 12 months
Loading...

Archive Staff Only

View Item View Item